We are pleased to announce that, starting in April 2026, we launched a new version of our ABC Transporter Vesicles derived from HEK cells, replacing the previous Sf9 cell-derived products.
Accordingly, the previous Sf9 cell-derived ABC Transporter Vesicles were discontinued at the end of September 2026.
Going forward, we will continue to provide ABC Transporter Vesicles derived from HEK cells. For customers who have previously used our Sf9 cell-derived products, we hope you will consider our new HEK cell-derived products for your future studies.
If you have any questions regarding the new products or the transition from the Sf9 cell-derived products, please feel free to contact us.
Products
A recent trend in drug development is to create new drugs that target a specific molecule identified by means of a genomic approach. Nevertheless, many drugs fail to reach clinical application, and costs associated with such unsuccessful drugs are high.
One of the major reasons for drop-out is inappropriate ADME (absorption, distribution, metabolism, and excretion) properties ofcandidates, resulting in low bioavailability or toxicity. It is, therefore, important to predict such problems at as early a stage as possible in the development process. GenoMembrane provides transporter reagents for this purpose.
GenoMembrane provides Transporter Membrane Vesicles and transporter expressing cell lines as research reagents.
